Clinical Trial Update: Tamoxifen-RAD001 Versus Tamoxifen Alone in Patients With Anti-aromatase Resistant Breast Metastatic Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial comparing tamoxifen with and without RAD001 in anti-aromatase resistant metastatic breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• RAD001 (everolimus)
• Tamoxifen (tamoxifen)

Snippet

Sponsor: ARCAGY/ GINECO GROUP | Conditions: Breast Neoplasms, mTor Protein | Phase 2 | Status: COMPLETED